STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] Sera Prognostics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Sera Prognostics' Form 144 shows a proposed sale of 7,094 Class A Common shares through Morgan Stanley Smith Barney on 08/08/2025. The filing states these shares were acquired by Restricted Stock Unit vesting on 08/08/2025 and lists an aggregate market value of 18,021 with 38,061,868 shares outstanding. The filing also discloses sales in the past three months: 5,132 shares on 05/08/2025 (gross proceeds 12,535) and 1,439 shares on 06/10/2025 (gross proceeds 2,136), totaling 6,571 shares sold for 14,671 gross proceeds. The notice includes the required representation that the seller does not possess undisclosed material adverse information.

Positive

  • The shares to be sold were acquired by Restricted Stock Unit vesting, indicating no cash purchase for the acquisition.
  • The proposed sale of 7,094 shares represents approximately 0.019% of the reported 38,061,868 shares outstanding, suggesting immaterial dilution.

Negative

  • None.

Insights

TL;DR: Proposed 7,094‑share sale is small relative to the 38,061,868 shares outstanding (about 0.019%).

The Form 144 shows the 7,094 shares to be sold were acquired via RSU vesting on 08/08/2025 and are to be sold through Morgan Stanley Smith Barney on the same date. Relative to the reported 38,061,868 shares outstanding, the proposed sale represents approximately 0.019% of outstanding shares, indicating the transaction is immaterial from a dilution perspective. The filing also documents two prior sales in the last three months totaling 6,571 shares and aggregate gross proceeds of 14,671, which similarly represent a very small fraction of outstanding stock.

TL;DR: This is a routine insider sale tied to RSU vesting and includes the standard certification about undisclosed material adverse information.

The submission is a standard Form 144 disclosure for shares acquired by restricted stock unit vesting and slated for sale via a broker. The document contains the required seller representation that no undisclosed material adverse information is known. Given the small absolute size of the proposed sale versus total shares outstanding, the filing appears procedural rather than indicative of a material governance or disclosure concern.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does SERA's Form 144 report?

The form reports a proposed sale of 7,094 Class A Common shares through Morgan Stanley Smith Barney on 08/08/2025 and prior sales in the past three months.

Who is the seller listed on the filing for SERA?

The seller shown in the past-sales section is John J. Boniface (address listed in the filing).

How were the 7,094 SERA shares acquired?

The filing states the shares were acquired on 08/08/2025 by Restricted Stock Unit vesting from the issuer.

What prior insider sales are disclosed for SERA?

Two prior sales are disclosed: 5,132 shares on 05/08/2025 (gross proceeds 12,535) and 1,439 shares on 06/10/2025 (gross proceeds 2,136), totaling 6,571 shares and 14,671 gross proceeds.

What are the aggregate market value and shares outstanding listed?

The filing lists an aggregate market value of 18,021 for the proposed sale and 38,061,868 shares outstanding.
Sera Prognostics, Inc.

NASDAQ:SERA

SERA Rankings

SERA Latest News

SERA Latest SEC Filings

SERA Stock Data

130.45M
33.40M
10.8%
64.96%
1.88%
Medical Devices
Services-medical Laboratories
Link
United States
SALT LAKE CITY